Press Releases

Circulating Tumor Cells (CTCs) in Patients’ Blood Detected by Epic Sciences are an “Accurate Representation” of Genetic Aberrations Found in Fresh Metastatic Tumor Samples

SAN DIEGO, Nov. 11, 2015 /PRNewswire/ -- Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform…

Epic Sciences’ Platform Capable of Single Cell CTC Identification Sequencing in Late Stage, Metastatic Cancer

SAN DIEGO, November 2, 2015 — After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations,…

Epic Sciences Present at World CDx Boston 2015

SAN DIEGO – September 2, 2015 -- Epic Sciences, Inc. (“Epic Sciences”), announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 –…

Epic Sciences Appoints Dave Henderson as Chief Information Officer

SAN DIEGO – August 26, 2015 - Epic Sciences, Inc. (“Epic Sciences”), announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at…

Epic Sciences’ Dr. Dena Marrinucci is Recognized as an Honoree of MIT Technology Review’s Annual Innovators Under 35 List

Today, MIT Technology Review revealed its annual list of Innovators Under 35. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world. For her work in…

Epic Sciences Publication Validates Unbiased Detection of Circulating Tumor Cells (CTCs) from a Liquid Biopsy

SAN DIEGO, August 11, 2015 /PRNewswire/ -- Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company’s no cell left behind™ platform. The data published demonstrate reproducible and…

Epic Sciences Appoints Dr. Greg Critchfield to Board of Directors

SAN DIEGO, July 13, 2015 -- Epic Sciences, Inc. ("Epic Sciences"), a private biotech company that develops diagnostics to personalize the treatment and management of cancer, announced today the appointment of Gregory C. Critchfield, M.D. to Epic Sciences'…

Epic Sciences Expands Partnership with LabCorp to Provide Circulating Tumor Cell Analysis And Support Oncology Clinical Trials in Asia

SAN DIEGO and SINGAPORE, July 7, 2015 -- Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to provide circulating tumor cell (CTC) technology and support oncology clinical trials in…

Epic Sciences Expands Silicon Valley Bank Credit Facility

SAN DIEGO, June 1, 2015 — Epic Sciences, Inc., a private diagnostics company that designs and develops products and offerings to personalize and advance the treatment and management of cancer, announced today that it has expanded the available credit…

Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-Patient Heterogeneity

SAN DIEGO, May 29, 2015 -- Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. This…